These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8907820)

  • 1. Systemic adjuvant therapy for breast cancer.
    Reed EC
    Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Questions and answers on adjuvant systemic therapy in breast carcinoma].
    Fey MF; Castiglione-Gertsch M
    Ther Umsch; 1996 Nov; 53(11):839-46. PubMed ID: 8984689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary adjuvant treatment of breast cancer.
    Akerley WL
    Surg Oncol Clin N Am; 1995 Oct; 4(4):685-99. PubMed ID: 8535905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Respective indications for hormone therapy, induction chemotherapy and adjuvant chemotherapy in breast cancer without clinically discernable distant metastases].
    Roy JA; Piccart MJ
    Rev Med Brux; 1995; 16(4):242-4. PubMed ID: 7481234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Breast carcinoma--adjuvant chemo- and hormone therapy].
    Fey MF
    Ther Umsch; 1998 Jul; 55(7):413-4. PubMed ID: 9702106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent advance in adjuvant therapy for breast cancer].
    Shimizu C; Watanabe T
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
    Stotter A
    Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent trends in the management of breast cancer. 3. Controversies in the use of adjuvant chemotherapy, hormonotherapy and radiotherapy for breast cancer.
    Donegan WL
    Can J Surg; 1992 Aug; 35(4):371-7. PubMed ID: 1498737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant systemic therapy for early breast cancer: progress and controversies.
    Hortobagyi GN
    Clin Cancer Res; 2001 Jul; 7(7):1839-42. PubMed ID: 11448893
    [No Abstract]   [Full Text] [Related]  

  • 19. 21. The adjuvant treatment of breast cancer.
    Kelleher M; Miles D
    Int J Clin Pract; 2003 Apr; 57(3):195-9. PubMed ID: 12723723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effectiveness of adjuvant systemic therapy in organ-preserving therapy of breast cancer].
    Semiglazov VF; Kanaev SV; Bugrova IL; Chagunava OL
    Vopr Onkol; 1998; 44(4):408-13. PubMed ID: 9807203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.